Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 EMD Millipore, Plasticell in Licensing Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

EMD Millipore, Plasticell in Licensing Pact

To distribute osteogenic medium for research

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

EMD Millipore, the Life Science division of Merck KGaA, has entered an agreement with Plasticell to distribute a single-application osteogenic medium discovered using the CombiCult screening system.
 
The osteogenic medium is serum- and xeno- free, more consistent and more potent than currently available formulations, according to the company. EMD Millipore has secured a license to distribute the medium globally for research purposes and Plasticell retains full rights for therapeutic applications.
 
The optimized osteogenic medium was developed using CombiCult to perform a rapid screen of 3,375 combinations of fully defined cell culture media. “The formulation of this medium in under three months from start to finish is a clear demonstration of the capability of the CombiCult technology to deliver market-leading products in record time,” said Dr. Jey Jeyakumar, the principal scientist who performed the factor screen and optimized the media formulation.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics